Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.45 |
| ▸ | EGFR | P00533 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 4/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24105224 | 0.95 | KDR (0.43) | KDREGFRKDM4ENPC1ALDH1A1 | |
| SCHEMBL30371277 | 0.88 | BRD4 (0.42) | KDREGFRTTKAURKA | |
| SCHEMBL22125168 | 0.88 | TTK (0.43) | KDRALDH1A1HPGDTTK | |
| SCHEMBL30167878 | 0.87 | TTK (0.41) | KDREGFRALDH1A1TTKAURKA | |
| SCHEMBL24105238 | 0.87 | TTK (0.41) | KDREGFRALDH1A1TTKAURKA | |
| Hydrochloric Acid SCHEMBL30168139 | 0.86 | TTK (0.40) | KDREGFRALDH1A1TTKAURKA | |
| Trifluoroacetic Acid SCHEMBL30168162 | 0.83 | TTK (0.38) | KDREGFRALDH1A1TTKAURKA | |
| SCHEMBL24104678 | 0.81 | TTK (0.44) | KDREGFRKDM4ENPC1ALDH1A1 | |
| SCHEMBL30168196 | 0.81 | TTK (0.44) | KDREGFRKDM4ENPC1ALDH1A1 | |
| SCHEMBL22124802 | 0.79 | TTK (0.45) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021249893-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | KDR 4773/4885EGFR 1449/4885KDM4E 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.